, Volume 15, Issue 3, pp 201-203
Date: 27 Mar 2013

Personalized Therapy in Gynecological Cancer: A Reality in Clinical Practice?

Rent the article at a discount

Rent now

* Final gross prices may vary according to local VAT.

Get Access
This is an excerpt from the content

Personalised medicine has already transformed oncology practice for a number of cancers. The rationale for molecularly targeted therapies is that such agents are more selective and therefore hold the promise of greater efficacy and potentially lower toxicity than conventional chemotherapy. Trastuzumab, a monoclonal antibody against the HER2 receptor, revolutionized the management of HER2-positive (overexpression and/or gene amplification) breast cancer (15–20 % of all cases) and has had a major impact on survival in a group of patients that otherwise have a more aggressive clinical course. In lung cancer clinics, EGFR mutational status directs the use of EGFR inhibitors (erlotinib and gefitinib) and more recently, the rapid development of the EML4-ALK inhibitor, crizotinib, along with the validation of the companion diagnostic test, has led to the approval of crizotinib. This targeted agent has impressive results in the distinct subset of non-small cell lung cancer patients (approximat ...